Shareholders might have noticed that Sinopharm Group Co. Ltd. (HKG:1099) filed its interim result this time last week. The early response was not positive, with shares down 3.7% to HK$16.12 in the past week. Results were roughly in line with estimates, with revenues of CN¥283b and statutory earnings per share of CN¥2.29. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
After the latest results, the 15 analysts covering Sinopharm Group are now predicting revenues of CN¥584.1b in 2026. If met, this would reflect a reasonable 2.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 5.7% to CN¥2.40. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥591.0b and earnings per share (EPS) of CN¥2.45 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.
View our latest analysis for Sinopharm Group
It might be a surprise to learn that the consensus price target fell 7.2% to HK$21.21, with the analysts clearly linking lower forecast earnings to the performance of the stock price. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Sinopharm Group, with the most bullish analyst valuing it at HK$27.70 and the most bearish at HK$17.01 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Sinopharm Group shareholders.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Sinopharm Group's rate of growth is expected to accelerate meaningfully, with the forecast 4.3% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 2.4% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 4.6% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Sinopharm Group is expected to grow at about the same rate as the wider industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Sinopharm Group's future valuation.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Sinopharm Group going out to 2028, and you can see them free on our platform here..
You should always think about risks though. Case in point, we've spotted 1 warning sign for Sinopharm Group you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.